Answers are grounded in this paper and cite their sources.
This retrospective study reports improved visual acuity in centenarians with neovascular AMD, suggesting the need for personalized treatment.
Purpose: To report clinical characteristics of exudative neovascular age-related macular degeneration (AMD) in centenarian patients. Methods: A retrospective, longitudinal study conducted in two retinal referral centers in Europe. Clinical characteristics of neovascular AMD patients having at last follow up at least ≥ 100 years were reviewed. Results: Twenty-eight eyes from 14 patients (13 females), with a mean baseline age of 95.7 (SD 4.1) years and a mean follow-up duration of 89 months (39.9). The mean age at last follow-up was 102.4 (1.7) years. Most eyes (86%) presented type 1 macular neovascularization (MNV). At the last follow-up, best corrected visual acuity (BCVA) was stable or improved in 57% of eyes, with a mean final BCVA of 53 letters (21.8) Snellen equivalent 20/100. Eyes with better visual outcomes (>50 letters) had significantly higher baseline BCVA (p<0.001) and thicker subfoveal choroidal thickness (p=0.03). Macular hemorrhage (25%) and macular atrophy (53.6%) were associated with poorer BCVA. Conclusion: Centenarian patients with neovascular AMD can maintain vision with long-term anti-VEGF therapy. These findings underscore the need for tailored management strategies for the challenges faced by centenarians with neovascular AMD.
No takes yet. Share an insight, caveat, or question.
Capuano et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: